FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2397150638> ?p ?o ?g. }

• W2397150638 endingPage "1095" @default.
• W2397150638 startingPage "1085" @default.
• W2397150638 abstract "Despite the progress in diagnosis and treatment, prostate cancer (PCa) is one of the main causes for cancer-associated deaths among men. Recently, prostate-specific membrane antigen (PSMA) binding tracers have revolutionized the molecular imaging of this disease. The translation of these tracers into therapeutic applications is challenging because of high PSMA-associated kidney uptake. While both the tumor uptake and the uptake in the kidneys are PSMA-specific, the kidneys show a more rapid clearance than tumor lesions. Consequently, the potential of endoradiotherapeutic drugs targeting PSMA is highly dependent on a sustained retention in the tumor - ideally achieved by predominant internalization of the respective tracer. Previously, we were able to show that the pharmacokinetics of the tracers containing the Glu-urea-based binding motif can be further enhanced with a specifically designed linker. Here, we evaluate an eventual influence of the chelator moiety on the pharmacokinetics, including the tumor internalization. A series of tracers modified by different chelators were synthesized using solid phase chemistry. The conjugates were radiolabeled to evaluate the influence on the receptor binding affinity, the ligand-induced internalization and the biodistribution behavior. Competitive binding and internalization assays were performed on PSMA positive LNCaP cells and the biodistribution of the most promising compound was evaluated by positron emission tomography (PET) in LNCaP-tumor-bearing mice. Interestingly, conjugation of the different chelators did not cause significant differences: all compounds showed nanomolar binding affinities with only minor differences. PET imaging of the (68)Ga-labeled CHX-A''-DTPA conjugate revealed that the chelator moiety does not impair the specificity of tumor uptake when compared to the gold standard PSMA-617. However, strong differences of the internalization ratios caused by the chelator moiety were observed: differences in internalization between 15% and 65% were observed, with the CHX-A''-DTPA conjugate displaying the highest internalization ratio. A first-in-man PET/CT study proved the high tumor uptake of this (68)Ga-labeled PSMA-targeting compound. These data indicate that hydrophobic entities at the chelator mediate the internalization efficacy. Based on its specific tumor uptake in combination with its very high internalization ratio, the clinical performance of the chelator-conjugated Glu-urea-based PSMA inhibitors will be further elucidated." @default.
• W2397150638 created "2016-06-24" @default.
• W2397150638 creator A5010448744 @default.
• W2397150638 creator A5010632119 @default.
• W2397150638 creator A5014159559 @default.
• W2397150638 creator A5024922998 @default.
• W2397150638 creator A5032880179 @default.
• W2397150638 creator A5033030371 @default.
• W2397150638 creator A5042184078 @default.
• W2397150638 creator A5044526711 @default.
• W2397150638 creator A5050947417 @default.
• W2397150638 creator A5080129940 @default.
• W2397150638 date "2016-01-01" @default.
• W2397150638 modified "2023-10-14" @default.
• W2397150638 title "Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals" @default.
• W2397150638 cites W1274250373 @default.
• W2397150638 cites W1544934333 @default.
• W2397150638 cites W1573450491 @default.
• W2397150638 cites W1904433804 @default.
• W2397150638 cites W1973942000 @default.
• W2397150638 cites W1991928498 @default.
• W2397150638 cites W1998403654 @default.
• W2397150638 cites W2014491165 @default.
• W2397150638 cites W2014999922 @default.
• W2397150638 cites W2027847537 @default.
• W2397150638 cites W2030870639 @default.
• W2397150638 cites W2030940240 @default.
• W2397150638 cites W2033819744 @default.
• W2397150638 cites W2038578630 @default.
• W2397150638 cites W2043601120 @default.
• W2397150638 cites W2055028529 @default.
• W2397150638 cites W2063649715 @default.
• W2397150638 cites W2064522544 @default.
• W2397150638 cites W2080006760 @default.
• W2397150638 cites W2086412457 @default.
• W2397150638 cites W2097629605 @default.
• W2397150638 cites W2106058419 @default.
• W2397150638 cites W2109699675 @default.
• W2397150638 cites W2111399643 @default.
• W2397150638 cites W2115158465 @default.
• W2397150638 cites W2116511683 @default.
• W2397150638 cites W2123987346 @default.
• W2397150638 cites W2125363072 @default.
• W2397150638 cites W2125398839 @default.
• W2397150638 cites W2134019417 @default.
• W2397150638 cites W2134364976 @default.
• W2397150638 cites W2139529507 @default.
• W2397150638 cites W2143802196 @default.
• W2397150638 cites W2151048211 @default.
• W2397150638 cites W2152768384 @default.
• W2397150638 cites W2155421560 @default.
• W2397150638 cites W2155847415 @default.
• W2397150638 cites W2160881737 @default.
• W2397150638 cites W2164905930 @default.
• W2397150638 cites W2170033391 @default.
• W2397150638 cites W2170794639 @default.
• W2397150638 cites W2171637628 @default.
• W2397150638 cites W2573642578 @default.
• W2397150638 doi "https://doi.org/10.7150/thno.13448" @default.
• W2397150638 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4893637" @default.
• W2397150638 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27279903" @default.
• W2397150638 hasPublicationYear "2016" @default.
• W2397150638 type Work @default.
• W2397150638 sameAs 2397150638 @default.
• W2397150638 citedByCount "57" @default.
• W2397150638 countsByYear W23971506382016 @default.
• W2397150638 countsByYear W23971506382017 @default.
• W2397150638 countsByYear W23971506382018 @default.
• W2397150638 countsByYear W23971506382019 @default.
• W2397150638 countsByYear W23971506382020 @default.
• W2397150638 countsByYear W23971506382021 @default.
• W2397150638 countsByYear W23971506382022 @default.
• W2397150638 countsByYear W23971506382023 @default.
• W2397150638 crossrefType "journal-article" @default.
• W2397150638 hasAuthorship W2397150638A5010448744 @default.
• W2397150638 hasAuthorship W2397150638A5010632119 @default.
• W2397150638 hasAuthorship W2397150638A5014159559 @default.
• W2397150638 hasAuthorship W2397150638A5024922998 @default.
• W2397150638 hasAuthorship W2397150638A5032880179 @default.
• W2397150638 hasAuthorship W2397150638A5033030371 @default.
• W2397150638 hasAuthorship W2397150638A5042184078 @default.
• W2397150638 hasAuthorship W2397150638A5044526711 @default.
• W2397150638 hasAuthorship W2397150638A5050947417 @default.
• W2397150638 hasAuthorship W2397150638A5080129940 @default.
• W2397150638 hasBestOaLocation W23971506381 @default.
• W2397150638 hasConcept C111919701 @default.
• W2397150638 hasConcept C112705442 @default.
• W2397150638 hasConcept C116569031 @default.
• W2397150638 hasConcept C121608353 @default.
• W2397150638 hasConcept C12554922 @default.
• W2397150638 hasConcept C126322002 @default.
• W2397150638 hasConcept C134306372 @default.
• W2397150638 hasConcept C136339569 @default.
• W2397150638 hasConcept C139770010 @default.
• W2397150638 hasConcept C150903083 @default.
• W2397150638 hasConcept C170493617 @default.
• W2397150638 hasConcept C185592680 @default.
• W2397150638 hasConcept C197336794 @default.

• next